Boosting the immune system after transplant: could 'Killer' cells prevent relapse?
NCT ID NCT07692607
First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests whether giving patients their own specially grown immune cells (called cytokine-induced killer cells) shortly after a stem cell transplant is safe. The trial enrolls adults with lymphoma who are receiving a transplant of their own stem cells. Researchers will monitor side effects and check for viral infections over two years, while also tracking whether the cancer stays away.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cytokine-induced killer (CIK) cells
- What this could lead to
- If safe, CIK cells could become a standard addition to stem cell transplants, potentially lowering the chance of cancer returning.
- What could go wrong
- This is a small early safety study with only 25 participants, so it cannot prove effectiveness. There is a risk of side effects like infections or immune reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Catholic University of Korea Seoul St.Mary's Hospital
Seoul, 06591, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.